The Cervical Cancer Treatment Market Size was valued at USD 6.19 Billion in 2023 and is projected to grow from USD 6.61 Billion in 2024 to USD 10.53 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.99% during the forecast period (2024 - 2032).The expanding demand for cervical cancer early diagnosis and treatment are the key market drivers enhancing the market growth.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Dr. Reddy’s Versavo (Bevacizumab) has biosimilar ambitions in the UK that resulted in the drug being launched in March 2024. Additionally, it is also the first company to have one authorized and introduced into Europe. Anti-angiogenic therapy ensures that Bevacizumab remains the first-line treatment for progressive metastatic cancer. This recombinant antibody, which has been humanized, can tie to and neutralize the vascular endothelial growth factor (VEGF), hence preventing the growth of tumors and angiogenesis. This is used in treating Metastatic colorectal cancer, non-squamous non-small cell lung cancer advanced stage, recurrent glioblastoma, metastatic renal cell carcinoma, advanced cervical cancer, ovarian cancer, and metastatic breast cancer.
It was this month that YuTuo®, a fully human anti-PD-1 monoclonal antibody GLS-010, became a commercial-stage biopharmaceutical company, and with it came its approval by China National Medical Products Administration (NMPA) for sale in September 2023. It is meant for R/M CC patients with positive PD-L1 expression (CPS≥1) who have progressed on or after platinum-based chemotherapy. Zimberelimab is the third global immune checkpoint inhibitor (ICI) antibody for cervical cancer, and it is the one that has been endorsed in China only.
The Hologic, Inc. (Nasdaq: HOLX) was cleared by the United States Food Drug Administration FDA to introduce a new Genius™ Digital Diagnostics System and Genius™ Cervical AI Algorithm in February 2024. It is, therefore, the world’s first digital cytology system approved by the FDA using deep learning-based artificial intelligence AI-augmented with advanced volumetric imaging technology to identify precancerous lesions and cervical cancer cells at an early stage. According to its most recent update, the American Cancer Society estimated that in 2024, approximately 13,820 cases of invasive cervical cancer will be diagnosed in the United States, leading to the death of about 4,360 women. Early detection and identification of cervical cancer are key factors for its prevention and treatment.
Market CAGR for cervical cancer treatment is being driven by the rising HPV Use and Pap Tests. According to cancer statistics, over 80% of instances of cervical cancer occur in women from low-resource and developing nations. The difficulty of implementing cytology-based screening programs also dramatically prolongs the time between cervical cancer diagnosis and treatment in countries like India. According to medical professionals, a thorough pre-screening approach is essential for spotting early cervical epithelial alterations. The Pap-Smear test remains the most popular screening procedure for precancerous cervical intraepithelial neoplasia and early-stage invasive cervical cancer. During surgery for cervical cancer, pelvic lymph nodes may be removed to look for signs of cancer spread. The immune system is powerless to stop the fast growth of tumor cells. New drugs called immune checkpoint inhibitors "reset" the immune system. It has been discovered that they are effective in treating several malignancies. Some high-risk HPV types associated with cervical cancer are preventable with vaccines. The HPV subtypes that cause 90% of cervical malignancies are the target of the presently available vaccines.
Government funding is the main source for upgrading the healthcare infrastructure in developing countries, which is likely to expand access to healthcare. It is predicted that this will lead to an increase in demand for cervical cancer therapies. Due to the growth in the frequency of chronic cardiac illnesses, notably cervical cancer, in emerging countries, the worldwide market for cervical cancer therapy offers attractive potential. Further advancements led to the US Food and Medicine Administration (FDA) approving Merck's medicine Keytruda, which intends to offer a second-line alternative for treating persistent, recurring, and metastatic cervical cancer. In a trial by the NIH, TIL treatment showed total remission of cervical cancer that had migrated to other organs. Compared to low-risk, The E6 or E7 gene that has been activated determines the HPV strains. E6's affinity for p53 causes its destruction by proteolysis. But when E7 binds to retinoblastoma, it displaces previously attached transcription factors, stops the cell cycle, and blocks the control of apoptosis. Other things, including oral contraceptives, smoking, and HIV infection, can also cause this condition.
The market under study has experienced significant expansion, attributable to the rising incidence of cervical cancer in women worldwide. Cervical cancer would be the fourth most common illness among women globally by 2020, with 604,000 new cases and 342,000 fatalities, according to WHO Updates from February 2022. Nearly 90% of new cases and fatalities globally in 2020 will occur in low- and middle-income nations. The industry is projected to expand as more individuals utilize cervical cancer diagnostic tests to identify early symptoms of the illness. Thus, driving the Cervical Cancer Treatment market revenue. Thus, driving the Cervical Cancer Treatment market revenue.
The Cervical Cancer Treatment market segmentation, based on type includes squamous cell carcinomas, adenocarcinomas, and adenosquamous carcinomas. The squamous cell carcinomas segment dominated the market, accounting for 45% of market revenue. The early detection and diagnosis of SCC are aided by the routine use of Pap tests for screening. Cervical adenocarcinoma is more common in women of specific racial groups, such as Hispanic and African-American women. SCC and adenocarcinoma may be separated from one another based on the histology, which can be observed under a microscope.
The Cervical Cancer Treatment market segmentation, based on treatment includes surgery, radiation therapy, chemotherapy, targeted therapy. The surgery segment dominated the market. A cone biopsy may be used to remove a small cervical cancer. During this procedure, a cone-shaped section of cervical tissue is removed, protecting the cervix from damage. The most common form of treatment for early-stage cervical cancers is a radical hysterectomy, which involves the removal of the cervix, uterus, a portion of the vagina, and nearby lymph nodes. Early-stage cervical cancer can be treated with a hysterectomy, which also serves to stop recurrence. But pregnancy is not feasible if the uterus is gone.
The Cervical Cancer Treatment market segmentation, based on End User, includes cancer care centers, pharmacies, and others. The cancer care centers generated the most income. Middle-aged women all over the world are severely burdened by the disease of cervical cancer. A middle-class person's initial point of contact for medical treatment is also the neighbourhood hospital.
Figure 1: Cervical Cancer Treatment Market, by End User, 2023 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American Cervical Cancer Treatment market area will dominate this market, because of large companies that specialise in treating cervical cancer, technical advancements, and a growth in the number of hospitals. The incidence of cervical cancer among females is rising in North America. Rising illness prevalence, consumer awareness, and advancements in oncological disease diagnostic and treatment technologies were all cited as causes for this.
Further, the major countries studied in the market report are The US, Canada, German, India, Australia, France, the UK, Italy, Spain, China, Japan, South Korea, and Brazil.
Figure 2: CERVICAL CANCER TREATMENT MARKET SHARE BY REGION 2023 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe has the second-largest market share for Cervical Cancer Treatment. Europe controls a sizable percentage of the market for therapies for the disease as a result of technical breakthroughs and the increased frequency of cervical cancer on the region. The market is expanding as a result of the favourable reimbursement environment and well-known regional and worldwide companies. Furthermore, the German Cervical Cancer Treatment market dominated, while the UK Cervical Cancer Treatment market grew fastest in Europe.
From 2023 to 2032, the Asia-Pacific Cervical Cancer Treatment Market will develop at the quickest CAGR. A rise in consumer awareness, and an increase in the number of health programmes by private and governmental organisations. Furthermore, China's Cervical Cancer Treatment market had the highest market share, whereas India's Cervical Cancer Treatment market was the Asia-Pacific region's fastest growing.
Cervical Cancer Treatment Key Market Players & Competitive Insights
Leading market companies are extensively spending R&D on increasing their product lines, which will help the Cervical Cancer Treatment market grow even more. Important market developments include new product releases, acquisitions and mergers, contractual agreements, greater investments, and collaboration with other organizations. The Cervical Cancer Treatment industry must produce cost-effective merchandise to flourish and thrive in a more competitive and increasing market climate.
Manufacturing locally to reduce operating costs is an effective business strategy manufacturers use in the worldwide Cervical Cancer Treatment industry to serve clients and expand the market sector. The Cervical Cancer Treatment industry has provided some of the most important benefits recently. Karkinos Healthcare Pvt. Ltd, Becton, Dickinson and Business and other major companies in the Cervical Cancer Treatment market are aiming to enhance market demand by investing in research and development activities.
Karkinos Healthcare Pvt. Ltd., a technology-led oncology platform with a purpose, specializes in creating and providing customized cancer care solutions. The organization aims to establish "cancer centers without walls," focusing on solving the accessibility or cost gaps in cancer care. It is led by a combination of highly regarded medical experts and technologists worldwide. In June 2022, In collaboration with the physicians and nurses of the Karkinos network of hospitals, Karkinos Healthcare introduced CerviRaksha, a first-of-its-kind clinically validated HPV test prequalified by the World Health Organisation and certified by the FDA.
The American multinational medical technology business Becton, Dickinson and Business, better known as BD, produces and markets reagents, instrument systems, and medical devices. In some regions, BD also offers consulting and analytics services.BD Medical also provides consultancy and analytics-related services in some locations. Healthcare systems, hospitals, and networks of healthcare providers are the primary target audiences for BD Medical's consulting services. Biosciences and Integrated Diagnostic Solutions are examples of business units. Offerings include unique reagents and assays, flow cytometry and multi-omics tools for immunology research, microbiology and molecular diagnostics, lab automation and informatics, and preanalytical solutions for sample management. In June 2021, Becton, Dickinson, and Company released the first self-collection HPV screening claims in the industry and were CE marked by the IVD Directive 98/79/EC.
Key Companies in the Cervical Cancer Treatment market include
GlaxoSmithKline
ALLERGAN
Actavis Pharma Company
Eli Lilly and Company
Alnylam Pharmaceuticals, Inc
Hetero
Biocon
Novartis
Genentech USA,
Cervical Cancer Treatment Industry Developments
November 2023: Merck & Co., Inc. announces that its investigational drug, KEYTRUDA® (pembrolizumab), has been granted FDA Breakthrough Therapy Designation for the treatment of recurrent or metastatic cervical cancer. KEYTRUDA is an immunotherapy drug that targets PD-1, a protein that helps cancer cells evade the immune system.GlaxoSmithKline plc announces that its investigational drug, Jemperli® (dostarlimab), has been granted FDA Orphan Drug Designation for the treatment of cervical cancer. Jemperli is an immunotherapy drug that targets PD-1, and it has shown promising results in early clinical trials in patients with cervical cancer.Bristol Myers Squibb Company announces that its investigational drug, Opdivo® (nivolumab), has been granted FDA Breakthrough Therapy Designation for the treatment of recurrent or metastatic cervical cancer. Opdivo is an immunotherapy drug that targets PD-1, and it has shown promising results in early clinical trials in patients with cervical cancer.
October 2023: Roche Diagnostics announces the launch of its new cobas HPV Test, which is the first FDA-approved test to detect all 14 high-risk HPV strains in a single assay. The cobas HPV Test is designed to help improve the accuracy of cervical cancer screening and to reduce the number of women who need to undergo unnecessary follow-up testing.BD (Becton, Dickinson and Company) announces the launch of its new BD Onclarity™ HPV Assay, which is a highly sensitive and specific test for the detection of high-risk HPV. The BD Onclarity HPV Assay is designed to help improve the early detection of cervical cancer and to reduce the number of women who develop this disease.
September 2023: Hologic, Inc. announces the launch of its new ThinPrep® Vision™ Cervical Cancer Screening System, which is a next-generation cervical cancer screening system that uses artificial intelligence to help identify precancerous and cancerous cells in cervical specimens. The ThinPrep Vision Cervical Cancer Screening System is designed to improve the accuracy of cervical cancer screening and to reduce the number of women who develop this disease.Qiagen N.V. announces the launch of its new QIAamp® Viral RNA Mini Kit, which is a high-performance kit for the extraction of viral RNA from cervical specimens. The QIAamp Viral RNA Mini Kit is designed to improve the accuracy of cervical cancer testing and to reduce the number of false negative results.
Squamous Cell Carcinomas
Adenocarcinomas
Adenosquamous Carcinomas
Surgery
Radiation Therapy
Chemotherapy
Targeted Therapy
Cancer Care Centers
Pharmacies
Others
| Report Attribute/Metric | Details |
| Market Size 2023 | USD 6.19Billion |
| Market Size 2024 | USD 6.61 Billion |
| Market Size 2032 | USD 10.53 Billion |
| Compound Annual Growth Rate (CAGR) | 5.99% (2024-2032) |
| Base Year | 2023 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2018- 2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Type, End User, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The US, Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Pfizer Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, ALLERGAN, Actavis Pharma Company, Eli Lilly and Company, Alnylam Pharmaceuticals, Inc, Hetero, Biocon, Novartis, Genentech USA, and others |
| Key Market Opportunities | Increasing demand for early diagnosis and treatment of cervical cancer |
| Key Market Dynamics | Increasing prevalence of cervical cancer |
Frequently Asked Questions (FAQ) :
The Cervical Cancer Treatment market size was valued at USD 6.19 Billion in 2023.
The market is projected to grow at a CAGR of 5.99% during the forecast period, 2024-2032.
North America had the largest share in the market
The key players in the market are Pfizer Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, ALLERGAN, Actavis Pharma Company.
The Squamous Cell Carcinomas dominated the market in 2022.
The cancer care centers had the largest share in the market.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
